WO2014170493A3 - Alphavirus vector - Google Patents

Alphavirus vector Download PDF

Info

Publication number
WO2014170493A3
WO2014170493A3 PCT/EP2014/058028 EP2014058028W WO2014170493A3 WO 2014170493 A3 WO2014170493 A3 WO 2014170493A3 EP 2014058028 W EP2014058028 W EP 2014058028W WO 2014170493 A3 WO2014170493 A3 WO 2014170493A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterologous protein
alphavirus vector
sequence
nsp3
nsp1
Prior art date
Application number
PCT/EP2014/058028
Other languages
French (fr)
Other versions
WO2014170493A2 (en
Inventor
Clayton BEARD
Giulietta MARUGGI
Peter W. Mason
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2014170493A2 publication Critical patent/WO2014170493A2/en
Publication of WO2014170493A3 publication Critical patent/WO2014170493A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention generally relates to recombinant alphavirus vectors comprising a 5 ' UTR, sequences encoding non-structural genes nsP1, nsP2, nsP3, and nsP4, and a sequence that is operably linked to an expression control sequence and encoding a heterologous protein; engineered to produce desired levels of heterologous protein expression and/or interferon induction.
PCT/EP2014/058028 2013-04-19 2014-04-19 Alphavirus vector WO2014170493A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13164381.9 2013-04-19
EP13164381 2013-04-19

Publications (2)

Publication Number Publication Date
WO2014170493A2 WO2014170493A2 (en) 2014-10-23
WO2014170493A3 true WO2014170493A3 (en) 2014-12-11

Family

ID=48141801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/058028 WO2014170493A2 (en) 2013-04-19 2014-04-19 Alphavirus vector

Country Status (1)

Country Link
WO (1) WO2014170493A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
US10538786B2 (en) 2016-04-13 2020-01-21 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
KR20190082226A (en) * 2016-10-17 2019-07-09 신테틱 제노믹스, 인코포레이티드. Recombinant viral replicon systems and uses thereof
BR112019011661A2 (en) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION
EA202091517A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND DEVICE FOR DELIVERY OF VACCINES AGAINST HEPATITIS B VIRUS (HBV)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
WO2019143949A2 (en) 2018-01-19 2019-07-25 Synthetic Genomics, Inc. Induce and enhance immune responses using recombinant replicon systems
EP3990648A1 (en) * 2019-06-27 2022-05-04 EMD Millipore Corporation Cell expansion with self-replicating rna vectors expressing immortalization proteins
US11759515B2 (en) 2020-03-09 2023-09-19 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
JP2023524055A (en) * 2020-04-30 2023-06-08 ブイエルピー・セラピューティクス・インコーポレイテッド cytokine immunotherapy
IL305676A (en) 2021-03-19 2023-11-01 Tiba Biotech Llc Artificial alphavirus-derived rna replicon expression systems

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113782A1 (en) * 2004-05-18 2005-12-01 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
WO2011139717A1 (en) * 2010-04-26 2011-11-10 Novartis Ag Improved production of virus replicon particles in packaging cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113782A1 (en) * 2004-05-18 2005-12-01 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
WO2011139717A1 (en) * 2010-04-26 2011-11-10 Novartis Ag Improved production of virus replicon particles in packaging cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEREGIN A V ET AL: "TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 30, 5 July 2010 (2010-07-05), pages 4713 - 4718, XP027118985, ISSN: 0264-410X, [retrieved on 20100702] *

Also Published As

Publication number Publication date
WO2014170493A2 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
WO2014170493A3 (en) Alphavirus vector
ZA201904814B (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2012170431A3 (en) Improved geneswitch systems
WO2013063383A3 (en) Vectors encoding rod-derived cone viability factor
MX362513B (en) Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof.
ZA201907716B (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
MX363427B (en) Psicose epimerase mutant and method for preparing psicose by using same.
EP3626274A3 (en) Recombinant promoters and vectors for protein expression in liver and use thereof
WO2016075473A3 (en) Factor ix gene therapy
WO2015200555A3 (en) Rna modification to engineer cas9 activity
EP3505629A4 (en) Sirna of human interleukin 6, recombinant expression car-t vector, and construction method and use thereof
MX2018010842A (en) Aav-mediated expression using a synthetic promoter and enhancer.
EA202190907A1 (en) REPLICONS BASED ON ALPHAVIRUS FOR THE ADMINISTRATION OF BIOTHERAPEUTIC AGENTS
MX2018010850A (en) Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses.
NZ628270A (en) Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
WO2019056015A3 (en) A strong insulator and uses thereof in gene delivery
MX2016009149A (en) Improved enzyme variants of lactase from kluyveromyces lactis.
MX2020006567A (en) Alphavirus replicon particle.
ZA201803442B (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EP4055174A4 (en) Transgene cassettes, aav vectors and aav viral vectors for the expression of human codon-optimized slc6a1
GB2547115A (en) Craft for use on a body of water and transport and control system therefore
IN2015DN00512A (en)
MX2016011300A (en) Recombinant isfahan viral vectors.
HRP20210265T1 (en) Telomerase reverse transcriptase-based therapies
PH12019500578A1 (en) New promoters

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14718594

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14718594

Country of ref document: EP

Kind code of ref document: A2